The Zurich-based medtech firm Xeltis has raised a total of 32 million euros as part of a Series D2 financing round. The company plans to use this fresh capital to progress its most advanced program, a vascular access graft known as aXess, to pivotal clinical trials, further details of which can be found in a press release.
For this financing round, existing investors such as Grand Pharma from Hong Kong and EQT Life Sciences from Stockholm in Sweden were joined by the DaVita Venture Group from Denver in the US state of Colorado and Invest-NL based in the Dutch capital of Amsterdam, among other international investors, the company writes in the press release.
“The strategic support of Grand Pharma and DaVita alongside our existing investor base represents a strong validation of our technology and potential to transform the landscape of cardiovascular surgery”, comments Eliane Schutte, CEO of Xeltis, in the press release. She and her team now intend to continue focusing on advancing the clinical studies for aXess in addition to exploring next steps in other application areas.
In addition to raising capital, Xeltis has also entered into a licensing agreement with Grand Pharma for aXess and other potential hemodialysis products developed on the same technology platform. This gives the Chinese pharmaceutical company exclusive rights to develop, produce and market these products in the Greater China region.
Xeltis was founded in 2006 as a spin-off from the University of Zurich. Later, Xeltis merged with the Dutch firm Qts/e and has since operated headquarters in both Zurich and Eindhoven.
